These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9616069)

  • 1. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D
    N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract]   [Full Text] [Related]  

  • 2. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F
    Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

  • 4. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F; Nashan B; Light S
    Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F; Einollahi B; Firoozan A; Nafar M; Yadegari H; Moghaddam SM; Simforoosh N; Basiri A; Farhangi S
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclizumab in live donor renal transplantation.
    Iverson AJ; Vick SC; Sarnacki CT; Wright FH
    Transplant Proc; 2000 Jun; 32(4):790-2. PubMed ID: 10856587
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 8. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H; Bäckman L; Tufveson G; Tydén G
    Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract]   [Full Text] [Related]  

  • 9. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B; Thervet E
    Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoclonal antibody approved for renal transplants.
    Am J Health Syst Pharm; 1998 Feb; 55(3):207-8. PubMed ID: 9492247
    [No Abstract]   [Full Text] [Related]  

  • 13. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
    Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
    Baczkowska T; Kukula K; Nowacka-Cieciura E; Cieciura T; Lewandowska D; Ciecierski R; Grochowiecki T; Rowinski W; Szmidt J; Durlik M; Lao M
    Transplant Proc; 2002 Mar; 34(2):551-2. PubMed ID: 12009620
    [No Abstract]   [Full Text] [Related]  

  • 15. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic monoclonal antibodies target kidney transplant rejection and cancer.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(3):379-80. PubMed ID: 9654869
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR
    Transplant Proc; 2002 Aug; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract]   [Full Text] [Related]  

  • 19. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J; Símová M; Nosková L; Teplan V; Vítko S
    Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract]   [Full Text] [Related]  

  • 20. New monoclonal antibodies to prevent transplant rejection.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):93-4. PubMed ID: 9774964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.